
==== Front
Sci Rep
Sci Rep
Scientific Reports
2045-2322
Nature Publishing Group UK London

39278971
72893
10.1038/s41598-024-72893-z
Article
Associations of head and neck cancers with herpes zoster in the preceding five years
Chen Chao-Hung 123
Xirasagar Sudha 34
Hung Shih-Han 567
Lin Herng-Ching 89
Chen Chin-Shyan stan@mail.ntpu.edu.tw

310
1 https://ror.org/015b6az38 grid.413593.9 0000 0004 0573 007X Department of Thoracic Surgery, Mackay Memorial Hospital, Taipei, Taiwan
2 https://ror.org/00t89kj24 grid.452449.a 0000 0004 1762 5613 Department of Medicine, MacKay Medical College, New Taipei City, Taiwan
3 https://ror.org/05031qk94 grid.412896.0 0000 0000 9337 0481 Research Center of Data Science on Healthcare Industry, College of Management, Taipei Medical University, Taipei, Taiwan
4 https://ror.org/02b6qw903 grid.254567.7 0000 0000 9075 106X Department of Health Services Policy and Management, Arnold School of Public Health, University of South Carolina, Columbia, USA
5 https://ror.org/05031qk94 grid.412896.0 0000 0000 9337 0481 Department of Otolaryngology, School of Medicine, Taipei Medical University, Taipei, Taiwan
6 https://ror.org/058y0nn10 grid.416930.9 0000 0004 0639 4389 Department of Otolaryngology, Wan Fang Hospital, Taipei, 110 Taiwan
7 https://ror.org/05031qk94 grid.412896.0 0000 0000 9337 0481 International Ph.D. Program in Medicine, College of Medicine, Taipei Medical University, Taipei, 110 Taiwan
8 https://ror.org/05031qk94 grid.412896.0 0000 0000 9337 0481 School of Health Care Administration, College of Management, Taipei Medical University, Taipei, Taiwan
9 https://ror.org/03k0md330 grid.412897.1 0000 0004 0639 0994 Research Center of Sleep Medicine, Taipei Medical University Hospital, Taipei, Taiwan
10 https://ror.org/03e29r284 grid.469086.5 0000 0000 9360 4962 Department of Economics, National Taipei University, New Taipei City, Taiwan
15 9 2024
15 9 2024
2024
14 215417 4 2024
11 9 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
This population-based study investigated the risk of having had prior herpes zoster within five years preceding a diagnosis of head and neck cancer. We conducted a case-control study that included 9,191 patients with a diagnosis of head and neck cancer in Taiwan’s Longitudinal Health Insurance Database 2010 and 36,764 matched controls. We assessed the odds of patients with head and neck cancer having had a diagnosis of herpes zoster during the five years preceding head and neck cancer using multiple logistic regression analysis. The prevalence of prior herpes zoster among the total sample was 4.6%, 7.9% and 3.8% among patients with and without head and neck cancer, respectively (p < 0.001). The odds ratio of herpes zoster among the head and neck cancer- versus control group was 2.198 (95% CI = 2.001 ~ 2.415) after adjusting for sociodemographic characteristics and hypertension, diabetes, hyperlipidemia, tobacco use disorder, HPV infection, and alcohol dependence syndrome. Statistically significant excess odds were observed for all specific subtypes of head and neck cancer except for sinonasal cancer. Herpes zoster infection within the 5 years preceding a diagnosis of head and neck cancer may be a harbinger of developing head and neck cancer.

Keywords

Head and neck cancer
Herpes zoster
Epidemiology
Subject terms

Oncology
Risk factors
issue-copyright-statement© Springer Nature Limited 2024
==== Body
pmcIntroduction

Cancers of the upper aerodigestive tract, such as the oral cavity, pharynx, nasopharynx, larynx, sinuses, and salivary glands, collectively constitute head and neck cancer (HNC)1,2. Head and neck cancer ranked among the dominant cancers globally, with 1.43 million newly reported cases and 0.51 million deaths in 2020. HNCs constituted 7.4% of the total 19.3 million new cancer cases worldwide, and caused 0.51 million deaths, for 5.1% of the total 10.0 million cancer deaths3. Over 90% of HNCs are squamous cell carcinomas3. The risk factors for HNC include exposure to carcinogens such as tobacco, alcohol consumption, and betel quid chewing, as well as male gender. Other risk factors include infectious agents such as human papillomaviruses and Epstein–Barr virus, poor oral hygiene, history of esophageal cancer, consuming hot beverages, occupational exposures (such as metal smelting and textile production), and consumption of preserved/processed foods containing nitrosamines4–7. However, only a fraction of HNC cases are accounted for by these known risk factors1.

The interaction between viral infection, the human immune system, and cancer biology is complex. Viruses like EBV, HPV, HBV, and HCV are implicated in 10–20% of human cancers. These viruses contribute to cancer through mechanisms like genomic instability and immune evasion. The immune system surveils and eliminates cancerous cells, but viruses can disrupt this process. This disruption can lead to unchecked cancer cell proliferation8. Oncogenic viruses have been valuable in cancer research, helping identify key molecular pathways involved in tumorigenesis and immune evasion, and guiding the development of targeted therapies and immunotherapies9.

Herpes zoster (HZ), also known as shingles, has been proposed as a likely risk factor for subsequent cancer, although the evidence remains controversial. HZ is caused by reactivation of latent infection with varicella-zoster virus (VZV), manifesting in the form of intermittent excruciating pain and discomfort along the affected unilateral dermatomes, followed by a maculopapular and vesicular rash in the area10. HZ can occur at any age, but it predominantly impacts older adults, with the incidence rising with advancing age11,12. The increase in HZ occurrence is notable from the age group of 50–60 years, reaching a prevalence of 11 cases per 1000 population aged 80 years and older13. VZV is thought to be restrained in a latent form by VZV-specific cell-mediated immunity11. Immunocompromised hosts face an elevated risk of developing HZ14. In a large, prospective follow-up cohort study in Australia by Qian et al. from 2006 to 2016 involving over 240,000 adults, patients with hematologic or solid cancer showed significantly elevated incidence of HZ prior to and after the cancer diagnosis compared to those without cancer, with adjusted hazard ratios of 3.74 and 1.30, respectively15. Anti-cancer therapy, such as radiation therapy, further increased the risk of HZ. The occurrence of HZ following radiation therapy was notably higher in the designated radiation field16. A nationwide population-based study also demonstrated that patients with HNC receiving radiation therapy are at an increased risk of herpes zoster17.

The exact connection between HZ and the risk of subsequent cancer incidence is not firmly established. Several epidemiologic studies have reported a possible link between HZ and subsequent cancer diagnoses; no study has specifically examined the association with subsequent HNC, which is a substantial contributor to the global cancer morbidity and mortality. Identifying factors with a potential link to HNC could enhance disease prevention, cancer downstaging, and assessing cancer prognosis. Further, exploring site-specific HNC classifications may facilitate better identification of cancer risk factors and the intricate pathways underlying cancer development.

The aim of this population-based case-control study was to examine HNC patients risk of having HZ in the five years preceding their HNC diagnosis compared to persons without HNC. Additionally, we assess site-classified HNCs to evaluate risk differences by cancer site.

Materials and methods

Database

We conducted a case-control study utilizing information from Taiwan’s Longitudinal Health Insurance Database 2010 (LHID2010). The LHID2010 has been extensively utilized by various researchers and scholars to investigate the epidemiology of diseases and treatments. The study was authorized by the Research Ethics Committee of National Taiwan University (202012EM075) and is in compliance with the Declaration of Helsinki. As we used deidentified administrative data provided by the LHID administration, informed consent was waived by the Research Ethics Committee of National Taiwan University.

Identification of study patients

We used a case-control methodology. The case group consisted of all patients in the LHID2010 aged ≥ 20 years old who received a first-time diagnosis of HNC, 9,191 persons. HNCs included all cancers defined as HNC, identified using the respective International Classification of Diseases (ICD) codes, oral cavity cancer (ICD-9-CM code 140, 141 (except 141.0; 141.6), 143, 144, 145.2; 145.3; 145.5, or 145 (except 145.2; 145.3; 145.5), ICD-10-CM codes C00, C02 except C02.4, C03, C04, C05, or C06), oropharynx (ICD-9-CM 141.0, 141.6 or 146, ICD-10-CM C01, C02.4, C09 or C10), larynx (ICD-9-CM 161, ICD-10-CM C32), hypopharynx (ICD-9-CM 148, ICD-10-CM C12 or C13), nasopharynx (ICD-9-CM 147, ICD-10-CM C11), sino-nasal (ICD-9-CM 160 (except 160.1), ICD-10-CM C31, C30.0), and salivary gland (ICD-9-CM 142, ICD-10-CM code C07, C08), during the period of 2011 to 2019. We assigned the date of their first-time HNC diagnosis as the index date.

We further employed propensity-score-matching method to retrieve the controls from the remaining beneficiaries aged ≥ 20 years old from the LHID2010. Beneficiaries with any claim before or after the selected cohort period showing a diagnosis of HNC were excluded. Using logistic regression modeling, propensity scores were calculated for all identified 9,191 patients with HNC and the remaining beneficiaries based on age, sex, monthly income, geographic location, urbanization level of the patient’s residence (5 levels, 1 most urbanized, 5 least urbanized), the presence of diabetes, hypertension, hyperlipidemia, and human papillomavirus (HPV) infection, tobacco use disorder and alcohol abuse/alcohol dependence syndrome. Finally, each sampled patient with HNC was matched with four control beneficiaries without HNC using the nearest neighbor random matching algorithm with caliper adjustment, using an a priori calipers value of +/-0.02. For cases, we assigned the index date as the date of first receipt of the HNC cancer diagnosis. For controls, the index date was assigned as the date when the corresponding control beneficiaries had their first ambulatory care visit during the index year of the matched case. The final study sample consisted of 9,191 patients with HNC and 36,764 controls without HNC.

Measures of exposure

We identified HZ based on ICD-9-CM code 0.53 or ICD-10-CM code B02 in any claim within a 5-year period prior to the index date.

Statistical analysis

We used the SAS system to conduct all statistical analyses. The differences in sociodemographic characteristics and the presence of medical comorbidities of patients with HNC and controls were studied using chi-square tests and t-tests. Multiple logistic regression modeling was utilized to evaluate the co-variate adjusted association between HNC and prior HZ taking the variables of sociodemographic characteristics and medical comorbidities (diabetes mellitus, hypertension or high blood pressure condition as well as hyperlipidemia or elevated levels of lipids in blood plasma, tobacco use disorder, HPV infection, and alcohol abuse/alcohol dependence syndrome) into consideration. We used odds ratios (OR) and their corresponding 95% confidence intervals (CIs) to present the difference in likelihoods of HZ occurrence among HNC patients compared to controls. We used a two-sided p-value < 0.05 as statistically significant.

Results

The sociodemographic characteristics and medical comorbidities among the sample patients are presented in Table 1. The HNC patient sample was dominated by men, 80.1%, and correspondingly the control group. The mean ages of the group with HNC and controls were similar, 60.4 ± 13.3 years and 60.5 ± 13.3, respectively, p = 0.493. The two groups were also similar on all the remaining sociodemographic and comorbidity variables, monthly income (p = 0.346), sex (p > 0.999), geographic location (p = 0.145), urbanization level (p = 0.758), diabetes (29.9% in both groups, p > 0.999), hyperlipidemia (38.7% in both groups, p > 0.999), hypertension (47.7% in both groups, p > 0.999), HPV infections (6.4% in both groups, p > 0.999), tobacco use disorder (10.3% in both groups, p > 0.999) and alcohol abuse/alcohol dependence syndrome (3.9% in both groups, p > 0.999).

Table 1 Demographic characteristics of patients aged 20 years or older with head and neck cancer (HNC) and propensity score-matched control patients.

Variable	Patients with HNC (n = 9191)	Propensity score-matched controls
(n = 36,764)	p value	
Total no.	%	Total no.	%	
Age, mean (SD)	60.4 (13.3)	60.5 (13.3)	0.493	
Males	7359	80.1	29,436	80.1	> 0.999	
Monthly Income					0.346	
< NT$1 ~ 15,841	2398	26.1	9362	25.5		
NT$15,841 ~ 25,000	3542	38.5	14,143	38.5		
≥NT$25,001	3251	35.4	13,259	36.1		
Geographic region					0.145	
Northern	3841	41.8	15,445	42.0		
Central	2372	25.8	9567	26.0		
Southern	2668	29.0	10,681	29.1		
Eastern	310	3.4	1071	2.9		
Residential urbanization level					0.758	
1 (most urbanized)	2308	25.1	9108	24.8		
2	2500	27.2	10,152	27.6		
3	1629	17.7	6585	17.9		
4	1325	14.4	5355	14.6		
5 (least urbanized)	1429	15.6	5564	15.1		
Hypertension	4381	47.7	17,524	47.7	> 0.999	
Hyperlipidemia	3555	38.7	14,220	38.7	> 0.999	
Diabetes	2752	29.9	11,008	29.9	> 0.999	
HPV infection	588	6.4	2352	6.4	> 0.999	
Tobacco use disorder	947	10.3	3788	10.3	> 0.999	
Alcohol abuse/dependence	357	3.9	1428	3.9	> 0.999	

Table 2 presents the rate of HZ occurrence among the total patients and the patients with HNC and controls. Among the full sample, 4.6% (2,122 patients) had a prior diagnosis of HZ, 7.9% among the HNC group and 3.8% among the control group (p < 0.001). Within HNC site classifications, significant differences between the cancer group and control group were observed in respect of oral cavity cancer (7.2% vs. 3.8%, respectively, p < 0.001), oropharynx (7.2% vs. 3.8%, p < 0.001), larynx (9.6% vs. 3.8%, p < 0.001), hypopharynx (6.2% vs. 3.8%, p < 0.001), nasopharynx (9.1% vs. 3.8%, p < 0.001), and salivary glands (11.6% vs. 3.8%, p < 0.001). We failed to observe a statistically significant difference between the sinonasal cancer group and controls (6.4% vs. 3.8%, p = 0.054).

Table 2 Prevalence rates of herpes zoster in the prior five years among patients with head and neck cancer (HNC)s vs. controls.

Cancer site	Had prior herpes zoster	No prior herpes zoster	P value	
n, %	n, %	
All head and neck cancers	722	7.9	8469	92.1	< 0.001	
Oral cavity	304	7.2	3895	92.8	< 0.001	
Oropharynx	62	7.2	803	92.8	< 0.001	
Larynx	66	9.6	620	90.4	< 0.001	
Hypopharynx	50	6.2	759	93.8	< 0.001	
Nasopharynx	196	9.1	1966	90.9	< 0.001	
Sinonasal cavities	13	6.4	190	93.6	0.054	
Salivary gland	31	11.6	236	88.4	< 0.001	
Controls	1,400	3.8	35,364	96.2		

Table 3 shows the OR for HZ of HNC patients versus controls, for all HNCs and HNC site classifications. After adjusting for sex, monthly income, age, geographic location, urbanization level, hypertension, HPV infection, hyperlipidemia, diabetes, tobacco use disorder and alcohol dependence syndrome, the OR for prior HZ was 2.198 (95% CI = 2.001 ~ 2.415, p < 0.001). Adjusted ORs were also significantly higher for oral cavity cancer 2.048 (95% CI = 1.798 ~ 2.333, p < 0.001), oropharynx 2.111 (95% CI: 1.616 ~ 2.758, p < 0.001), larynx 2.154 (95% CI = 1.654 ~ 2.805, p < 0.001), hypopharynx 1.744 (95% CI = 1.298 ~ 2.344, p < 0.001), nasopharynx 2.714 (2.311 ~ 3.186, p < 0.001), and salivary gland 2.993 (95% CI = 2.031 ~ 4.411, p < 0.001).

Table 3 Adjusted odds ratios of prior herpes zoster among patients with head and neck cancer (HNC) vs.controls.

Cancer site	Prior herpes zoster	
OR a (95% CI)	
All head and neck cancers	2.198c (2.001 ~ 2.415)	
Oral cavity	2.048c (1.798 ~ 2.333)	
Oropharynx	2.111c (1.616 ~ 2.758)	
Larynx	2.111c (1.616 ~ 2.758)	
Hypopharynx	1.744c (1.298 ~ 2.344)	
Nasopharynx	2.714c (2.311 ~ 3.186)	
Sinonasal cavities	1.415 (0.798 ~ 2.510)	
Salivary gland	2.993c (2.031 ~ 4.411)	
aAdjusted for age, sex, monthly income, geographic region, urbanization level, hypertension, diabetes, hyperlipidemia, tobacco use disorder, alcohol abuse/alcohol dependence syndrome and HPV infection; cp < 0.001.

Table 4 estimate the ORs of prior HZ among patients with HNC vs. controls by the infection timing of prior HZ. We found that the OR was similar regardless of the HZ infection time (year).

Table 4 Adjusted odds ratios of prior herpes zoster among patients with head and neck cancer (HNC) vs. controls by the occurrence timing of prior herpes zoster.

Presence of prior herpes zoster	Occurrence timing of herpes zoster prior to the index date	
Within one year	Within two years	Within three years	
Patients with HNCs
n, %	Controls
n, %	Patients with HNCs
n, %	Controls
n, %	Patients with HNCs
n, %	Controls
n, %	
Yes	156, 1.70%	240, 0.65%	312, 3.39%	523, 1.42%	475, 5.17%	799, 2.17%	
ORa (95% CI)	2.628c (2.145 ~ 3.219)	1.00	2.436c (2.113 ~ 2.808)	1.00	2.454c (2.185 ~ 2.755)	1.00	
Adjustedb OR (95% CI)	2.648c (2.161 ~ 3.246)	1.00	2.461c (2.134 ~ 2.839)	1.00	2.492c (2.218 ~ 2.801)	1.00	
aAdjusted for age, sex, monthly income, geographic region, urbanization level, hypertension, diabetes, hyperlipidemia, tobacco use disorder, alcohol abuse/alcohol dependence syndrome and HPV infection; cp < 0.001.

Discussion

Our study may be the first nationwide population-based study to report on HZ as a potential risk factor or prior harbinger for a subsequent diagnosis of head and neck cancer. We found about twice the odds of HZ in the prior 5 years among persons diagnosed with HNC. Of the overall sample, 4.6% had suffered from HZ in the prior five years, being 7.9% among patients with HNC, compared to 3.8% among controls. When categorized by the anatomic site, patients with cancer at all locations showed a higher rate of HZ than control patients, with the exception of sinonasal cancer, After adjustment for the covariates, the odds ratio for the HNC patients was 2.198 (95% CI = 2.001–2.415, p < 0.001), with statistically significantly increased odds observed for most subsite classifications (oral cavity, oropharynx, larynx, hypopharynx, nasopharynx, and salivary gland), and sinonasal cancer failing to attain statistical significant (p = 0.054).

Studies regarding whether HZ or not is associated with increased cancer likelihood subsequently have been inconsistent in their findings. Ragozzino and colleagues published the first population-based cohort study in 1982 assessing the risk of any type of cancer following a diagnosis of HZ18. They followed 590 patients in Rochester, Minnesota, for 9389 person-years after their diagnosis of herpes zoster, and reported a relative risk of 1.1, 95% CI 0.9–1.3. The study was limited by small sample size. However, they observed a slight elevation in the relative risks of colon and bladder tumors in women. Sørensen and colleagues reported on the risk of all types of cancer in a population-based study, using follow-up data on 10,588 hospitalized patients with HZ between 1977 and 1996 to investigate their subsequent risk of cancer19. In the first year, the relative risk (RR) for all types of cancer was 1.3 (95% CI 1.1–1.5), with a higher relative risk for hematologic cancer, 3.4 (95% CI 2.3–4.9). Buntinx and colleagues investigated the risk of a subsequent cancer diagnosis over 311,000 patient-years (1-year follow-up) of a general practitioner patient population in Belgium from 1994 to 2000 (most patients being women aged over 65 years). Among women aged 65 years or older, they identified a significantly increased risk of cancer among those with a HZ diagnosis. Wang and colleagues conducted a population-based retrospective study in 2012, examining 35,871 newly diagnosed patients with HZ in Taiwan from 2000 to 2008. They observed no association with subsequent cancer compared to the general population20. Their analysis did not account for confounding factors such as socioeconomic status and comorbidities. One systematic review and meta-analysis conducted by Schmidt et al. in 2016 reported an association between HZ and occult cancer. The pooled relative risk for any cancer was 1.42 (95% CI: 1.18, 1.71) across all follow-up durations, and 1.83 (95% CI: 1.17, 2.87) during Year 1 of follow-up19. A similar result was reported in a Taiwanese nationwide cohort study in 2020. The risk of subsequent cancer was modestly increased for one year or more after a diagnosis of HZ20. Multiple studies have explored the risk of specific cancers among patients with HZ. Compared to individuals without cancer, Qian et al. found that the risk of prior HZ diagnosis was increased among persons with hematological cancer (adjusted hazard ratio for 1–2 years prior, 2.01 [95% CI, 1.31–3.09]), but not for persons with solid tissue cancers15. Other studies have shown an association between HZ and subsequent lymphoid (or hematologic) neoplasms10,20,21.

Only one study had investigated the association between HZ and subsequent cancer in the head and neck region. In 2011, Ho et al. showed that individuals with herpes zoster ophthalmicus (HZO) had a 9.25-fold higher risk (95% CI, 5.51–15.55) of a subsequent cancer diagnosis compared to a propensity score-matched control group. They concluded that HZO could serve as a marker for increased cancer risk of cancer22. In their study, however, out of 658 cases of HZO, only 32 patients (4.86%) developed subsequent cancer during the study follow-up period of one year. Limited sample size and limited follow-up precluded additional exploration into specific cancer sites. Our study may be the first in the literature to demonstrate that HZ infection represents a higher likelihood of a subsequent diagnosis of head and neck cancer. Our findings held up within cancer sites, except for sinonasal cancer which could be due to statistical power limitations (p = 0.054) Further studies are needed for a more detailed understanding of the risk patterns by site.

Several potential mechanisms for the HZ-cancer link have been addressed in the literature. First, both HZ and HNC are associated with diminished cell-mediated immunity. The varicella zoster virus remains dormant until the cell-mediated immune system is weakened, allowing the virus to proliferate19. The reactivation of VZV further triggers immunologic mechanisms that weaken immune surveillance for cancer cells, enabling tumor escape22–25. Second, host immunity dysfunction may lead to the onset of either HZ or malignancy, with the possibility of either condition manifesting first22,25. Third, there is also a suggestion that HZ directly contributes to carcinogenesis26. Viruses can introduce alterations in the genome through incorporation of viral genes into the host genome21. The viral infection by itself can induce a state of chronic inflammation27. Both of these changes disturb normal cellular functions and promote cell proliferation and malignant change28,29.

There are some implications of our findings. Firstly, healthcare professionals should be alert to actively investigate patients presenting with HZ for cancer especially if they have symptoms of oncological significance or risk factors for cancer12,30,31. Secondly, additional evaluation of the patient’s immune response to zoster infection may be in order. Thirdly, administration of the HZ vaccine to immunocompromised individuals, particularly those with cell-mediated immune deficiency, may mitigate the risk of HNC by preventing HZ32.

Our study has three strengths. First, patients with HNC and those in the control group were obtained from the LHID2010 claims dataset. The utilization of this population-representative sample minimizes concerns of recall bias, selection bias, non-response bias (inherent in survey-based studies) and surveillance bias, as well as bias due to loss to follow-up. Second, the large, 99.7% Taiwanese population coverage by the National Health Insurance Program provided us with a substantial enough sample to investigate the association between HZ and HNC, and particularly sub-site cancers within HNC. Many prior studies exploring HZ and cancer have adjusted for a limited set of confounders, with only a few accountings for comorbidities. Our study carefully accounted for many relevant sociodemographic and disease covariates not examined in previous research (e.g., monthly income, geographic location, and urbanization level, other sociodemographics and comorbidities). Use of propensity scores to match HZ cases with comparison patients to achieve an appropriately comparable group improves the validity of the findings by maximally overcoming confounding. Finally, the identification of cases of malignant head and neck tumors in our study is both valid and definitive because the National Health Insurance Program administration mandates biopsy and histological confirmation to declare a cancer diagnosis for reimbursement and subsequent referral for treatment.

Despite the above strengths, some limitations should be noted. First, the HZ patients identified in the LHID2010 claims dataset represents only patients who had sought treatment for HZ and HNC. This concern may be largely mitigated in respect of HZ, given the intense cutaneous symptoms—burning pain, itching, hyperesthesia, and paresthesia over protracted periods of time, several days to weeks or months, which is likely to constrain them to seek medical attention. Given the comprehensive benefits covered by the National Health Insurance Program which includes coverage of cancer treatment, it is unlikely that persons with HNC will refrain from seeking treatment. Second, the study was unable to further explore the relationships with different anatomic locations of HZ, particularly facial and other anatomical areas. Finally the data on important patient characteristics and lifestyle factors (e.g., tobacco and alcohol consumption, betel quid chewing, poor oral hygiene) associated with HNC and HZ were unavailable in the claims data used in our study.

It should be noted that the study lacks verification methods to ensure the herpes zoster infection, as our study employed a blend of clinical and molecular diagnosis codes, incorporating including the PCR test, serum antigen, and antibody tests to detect Herpes Zoster infection cases. This methodology was selected due to non-obligatory use of the laboratory test in our healthcare system for managing associated illnesses. The research design aimed to encompass as many instances of Herpes Zoster as feasible while delving into the potential association with head and neck cancer, thereby resulting in diagnostic heterogeneity regarding Herpes Zoster detection. The identification of human Herpes Zoster virus infections was reliant on medical documentation, which could be impacted by the frequency of medical visits and testing procedures, consequently resulting in detection prejudice. Even though the laboratory examination is not obligatory for managing related illnesses in our healthcare network, it would be preferable if all Herpes Zoster patients were confirmed through PCR testing, with subtypes specified for further analysis.

Our study presents an opening by showing that within a 5-year period prior to an HNC diagnosis, HZ infection may serve as a potential risk factor for cancer or at least a marker of occult cancer. Moving beyond the epidemiologic evidence presented in this population-based dataset, it is necessary to verify the findings and confirm the direction of association, and potentially a causal link between the two entities. Future studies are warranted to clarify the temporal association between HZ and HNC. While the histological data for cases of HNC in our study based on health insurance is currently unavailable, it is imperative that future investigations consider conducting subgroup analyses to determine if there exist any disparities between cases of squamous cell carcinoma (SCC) and those of non-SCC. In addition, further studies are suggested to elucidate the biomedical pathways connecting HZ to HNC, and further, the potential for the HZ vaccine to influence the causal linkages that may be involved between HZ and cancer.

Author contributions

Conceptualization: CH, HC, CS; Data curation: CS; Formal analysis: CS; Methodology: HC, CS; Validation: CS; Writing - original draft: CH, HC, CS, SH, SX; Writing – critical review for content & editing: CH and SX. All authors reviewed the manuscript.

Data availability

The LHID2010 that support the findings of this study can be reached by researchers through a formal application process addressed to the HWDC, Department of Statistics, Ministry of Health and Welfare, Taiwan (https://dep.mohw.gov.tw/DOS/cp-5119-59201-113.html).

Declarations

Competing interests

The authors declare no competing interests.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

These authors have equally contributed to this work.
==== Refs
References

1. Gui L Obesity and head and neck cancer risk: a mendelian randomization study BMC Med. Genomics 2023 16 1 200 10.1186/s12920-023-01634-4 37620971
Gui, L. et al. Obesity and head and neck cancer risk: a mendelian randomization study. BMC Med. Genomics. 16 (1), 200 (2023).37620971 10.1186/s12920-023-01634-4
2. Mody MD Head and neck cancer Lancet 2021 398 10318 2289 2299 10.1016/S0140-6736(21)01550-6 34562395
Mody, M. D. et al. Head and neck cancer. Lancet. 398 (10318), 2289–2299 (2021).34562395 10.1016/S0140-6736(21)01550-6
3. Sung H Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries CA Cancer J. Clin. 2021 71 3 209 249 10.3322/caac.21660 33538338
Sung, H. et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71 (3), 209–249 (2021).33538338 10.3322/caac.21660
4. Chung CS Tag single nucleotide polymorphisms of alcohol-metabolizing enzymes modify the risk of upper aerodigestive tract cancers: HapMap database analysis Dis. Esophagus 2014 27 5 493 503 10.1111/j.1442-2050.2012.01437.x 23088731
Chung, C. S. et al. Tag single nucleotide polymorphisms of alcohol-metabolizing enzymes modify the risk of upper aerodigestive tract cancers: HapMap database analysis. Dis. Esophagus. 27 (5), 493–503 (2014).23088731 10.1111/j.1442-2050.2012.01437.x
5. Chung CS Endoscopic screening for second primary tumors of the Esophagus among Head and Neck Cancer patients Front. Oncol. 2022 12 906125 10.3389/fonc.2022.906125 35747824
Chung, C. S. et al. Endoscopic screening for second primary tumors of the Esophagus among Head and Neck Cancer patients. Front. Oncol. 12, 906125 (2022).35747824 10.3389/fonc.2022.906125
6. Panosetti E Multiple synchronous and metachronous cancers of the upper aerodigestive tract: a nine-year study Laryngoscope 1989 99 12 1267 1273 10.1288/00005537-198912000-00011 2601541
Panosetti, E. et al. Multiple synchronous and metachronous cancers of the upper aerodigestive tract: a nine-year study. Laryngoscope. 99 (12), 1267–1273 (1989).2601541 10.1288/00005537-198912000-00011
7. van de Ven S Screening for head and neck second primary tumors in patients with esophageal squamous cell cancer: a systematic review and meta-analysis United Eur. Gastroenterol. J. 2019 7 10 1304 1311 10.1177/2050640619856459
van de Ven, S. et al. Screening for head and neck second primary tumors in patients with esophageal squamous cell cancer: a systematic review and meta-analysis. United Eur. Gastroenterol. J. 7 (10), 1304–1311 (2019).10.1177/2050640619856459
8. McLaughlin-Drubin ME Munger K Viruses associated with human cancer Biochim. Biophys. Acta 2008 1782 3 127 150 10.1016/j.bbadis.2007.12.005 18201576
McLaughlin-Drubin, M. E. & Munger, K. Viruses associated with human cancer. Biochim. Biophys. Acta. 1782 (3), 127–150 (2008).18201576 10.1016/j.bbadis.2007.12.005
9. Fridman W Immunosurveillance in human non-viral cancers Curr. Opin. Immunol. 2011 23 2 272 278 10.1016/j.coi.2010.12.011 21237631
Fridman, W. et al. Immunosurveillance in human non-viral cancers. Curr. Opin. Immunol. 23 (2), 272–278 (2011).21237631 10.1016/j.coi.2010.12.011
10. Choi HG Increased risk of lymphoid malignancy in patients with herpes zoster: a longitudinal follow-up study using a national cohort BMC Cancer 2019 19 1 1148 10.1186/s12885-019-6349-y 31775678
Choi, H. G. et al. Increased risk of lymphoid malignancy in patients with herpes zoster: a longitudinal follow-up study using a national cohort. BMC Cancer. 19 (1), 1148 (2019).31775678 10.1186/s12885-019-6349-y
11. Thomas SL Hall AJ What does epidemiology tell us about risk factors for herpes zoster? Lancet. Infect. Dis 2004 4 1 26 33 10.1016/S1473-3099(03)00857-0 14720565
Thomas, S. L. & Hall, A. J. What does epidemiology tell us about risk factors for herpes zoster? Lancet. Infect. Dis. 4 (1), 26–33 (2004).14720565 10.1016/S1473-3099(03)00857-0
12. Cotton SJ The risk of a subsequent cancer diagnosis after herpes zoster infection: primary care database study Br. J. Cancer 2013 108 3 721 726 10.1038/bjc.2013.13 23361054
Cotton, S. J. et al. The risk of a subsequent cancer diagnosis after herpes zoster infection: primary care database study. Br. J. Cancer. 108 (3), 721–726 (2013).23361054 10.1038/bjc.2013.13
13. Dooling, K. L., Guo, A. & Patel, M. Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines. Available online: (2024). http://www.cdc.gov/mmwr/volumes/67/wr/mm6703a5.htm (accessed on 14 January MMWR Morb Mortal Wkly Rep, 2018. 67: pp. 103–108.
14. Yawn BP Herpes zoster recurrences more frequent than previously reported Mayo Clin. Proc. 2011 86 2 88 93 10.4065/mcp.2010.0618 21220354
Yawn, B. P. et al. Herpes zoster recurrences more frequent than previously reported. Mayo Clin. Proc. 86 (2), 88–93 (2011).21220354 10.4065/mcp.2010.0618
15. Qian J Risk of herpes Zoster Prior to and following Cancer diagnosis and treatment: a Population-based prospective cohort study J. Infect. Dis. 2018 220 1 3 11 10.1093/infdis/jiy625
Qian, J. et al. Risk of herpes Zoster Prior to and following Cancer diagnosis and treatment: a Population-based prospective cohort study. J. Infect. Dis. 220 (1), 3–11 (2018).10.1093/infdis/jiy625
16. Shimizuguchi T Radiation therapy and the risk of herpes zoster in patients with cancer Cancer 2020 126 15 3552 3559 10.1002/cncr.32926 32412661
Shimizuguchi, T. et al. Radiation therapy and the risk of herpes zoster in patients with cancer. Cancer. 126 (15), 3552–3559 (2020).32412661 10.1002/cncr.32926
17. Lee PY Incidence and time trends of herpes zoster among patients with head and neck cancer who did and did not undergo radiotherapy: a population-based cohort study PLoS One 2021 16 5 e0250724 10.1371/journal.pone.0250724 34014932
Lee, P. Y. et al. Incidence and time trends of herpes zoster among patients with head and neck cancer who did and did not undergo radiotherapy: a population-based cohort study. PLoS One. 16 (5), e0250724 (2021).34014932 10.1371/journal.pone.0250724
18. Ragozzino MW Risk of cancer after herpes zoster: a population-based study N Engl. J. Med. 1982 307 7 393 397 10.1056/NEJM198208123070701 6979711
Ragozzino, M. W. et al. Risk of cancer after herpes zoster: a population-based study. N Engl. J. Med. 307 (7), 393–397 (1982).6979711 10.1056/NEJM198208123070701
19. Sørensen HT The risk and prognosis of cancer after hospitalisation for herpes zoster: a population-based follow-up study Br. J. Cancer 2004 91 7 1275 1279 10.1038/sj.bjc.6602120 15328522
Sørensen, H. T. et al. The risk and prognosis of cancer after hospitalisation for herpes zoster: a population-based follow-up study. Br. J. Cancer. 91 (7), 1275–1279 (2004).15328522 10.1038/sj.bjc.6602120
20. Wang YP Risk of cancer among patients with herpes zoster infection: a population-based study Cmaj 2012 184 15 E804 E809 10.1503/cmaj.120518 22988158
Wang, Y. P. et al. Risk of cancer among patients with herpes zoster infection: a population-based study. Cmaj. 184 (15), E804–E809 (2012).22988158 10.1503/cmaj.120518
21. Liu YC Herpes zoster is associated with an increased risk of subsequent lymphoid malignancies - a nationwide population-based matched-control study in Taiwan BMC Cancer 2012 12 503 10.1186/1471-2407-12-503 23114019
Liu, Y. C. et al. Herpes zoster is associated with an increased risk of subsequent lymphoid malignancies - a nationwide population-based matched-control study in Taiwan. BMC Cancer. 12, 503 (2012).23114019 10.1186/1471-2407-12-503
22. Ho JD Xirasagar S Lin HC Increased risk of a cancer diagnosis after herpes zoster ophthalmicus: a nationwide population-based study Ophthalmology 2011 118 6 1076 1081 10.1016/j.ophtha.2010.10.008 21232800
Ho, J. D., Xirasagar, S. & Lin, H. C. Increased risk of a cancer diagnosis after herpes zoster ophthalmicus: a nationwide population-based study. Ophthalmology. 118 (6), 1076–1081 (2011).21232800 10.1016/j.ophtha.2010.10.008
23. Lenders JW Combined immunodeficiency preceding chronic lymphocytic leukemia Blut 1984 48 3 171 175 10.1007/BF00320340 6697005
Lenders, J. W. et al. Combined immunodeficiency preceding chronic lymphocytic leukemia. Blut. 48 (3), 171–175 (1984).6697005 10.1007/BF00320340
24. Lin WW Karin M A cytokine-mediated link between innate immunity, inflammation, and cancer J. Clin. Invest. 2007 117 5 1175 1183 10.1172/JCI31537 17476347
Lin, W. W. & Karin, M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J. Clin. Invest. 117 (5), 1175–1183 (2007).17476347 10.1172/JCI31537
25. Buntinx F Is herpes zoster a marker for occult or subsequent malignancy? Br. J. Gen. Pract. 2005 55 511 102 107 15720930
Buntinx, F. et al. Is herpes zoster a marker for occult or subsequent malignancy? Br. J. Gen. Pract. 55 (511), 102–107 (2005).15720930
26. Rogers RS Tindall JP Geriatric herpes zoster J. Am. Geriatr. Soc. 1971 19 6 495 504 10.1111/j.1532-5415.1971.tb01208.x 5094651
Rogers, R. S., Tindall, J. P. & 3rd and Geriatric herpes zoster. J. Am. Geriatr. Soc. 19 (6), 495–504 (1971).5094651 10.1111/j.1532-5415.1971.tb01208.x
27. Dave, S. S. Host factors for risk and survival in lymphoma. Hematology Am Soc Hematol Educ Program, 2010: pp. 255-8. (2010).
28. Engels EA Infectious agents as causes of non-hodgkin lymphoma Cancer Epidemiol. Biomarkers Prev. 2007 16 3 401 404 10.1158/1055-9965.EPI-06-1056 17337646
Engels, E. A. Infectious agents as causes of non-hodgkin lymphoma. Cancer Epidemiol. Biomarkers Prev. 16 (3), 401–404 (2007).17337646 10.1158/1055-9965.EPI-06-1056
29. Wyburn-Mason R Malignant change arising in tissues affected by herpes Br. Med. J. 1955 2 4948 1106 1109 10.1136/bmj.2.4948.1106 13260671
Wyburn-Mason, R. Malignant change arising in tissues affected by herpes. Br. Med. J. 2 (4948), 1106–1109 (1955).13260671 10.1136/bmj.2.4948.1106
30. Zaha M [Herpes zoster and malignancy] Masui 1993 42 9 1343 1346 8230723
Zaha, M. et al. [Herpes zoster and malignancy]. Masui. 42 (9), 1343–1346 (1993).8230723
31. Yamamoto M Gastrointestinal cancer and herpes zoster in adults Hepatogastroenterology 2003 50 52 1043 1046 12845977
Yamamoto, M. et al. Gastrointestinal cancer and herpes zoster in adults. Hepatogastroenterology. 50 (52), 1043–1046 (2003).12845977
32. Tayyar, R. & Ho, D. Herpes Simplex Virus and Varicella Zoster Virus infections in Cancer patients. Viruses, 15(2). (2023).
